Firebrick Pharma (ASX:FRE) intends to get its Nasodine nasal spray approved in all markets over the long term to receive royalties and license fees through its partners, according to a Wednesday filing with the Australian bourse.
In its investor update, Firebrick Pharma said it expects a decision on its application for Nasodine to be marketed as a nasal antiseptic in Europe in 2025. Once approved, the company plans to lodge its application in New Zealand and South Africa.
Nasodine is being marketed as a nasal cleanser in the US, where the company plans to pursue pharmacy distribution.
In the Philippines, the product is expected to be launched as a nasal antiseptic in 2025.
The pharmaceutical company's shares were up nearly 8% in recent Wednesday trade.
Price (AUD): $0.06, Change: $+0.004, Percent Change: +7.69%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。